ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications,

Slides:

Advertisements

Similar presentations

Diabetes in Pregnancy Screening.

Advertisements

VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.

February 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.

Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2016 ACC Expert Consensus Decision Pathway on the.

ALICE-PROTECT Study Yields Online Risk Prediction Tool in Diabetic Nephropathy From ESH 2016 | LB 1: Jean-Pierre Fauvel, MD CHU Lyon, Hôpital E Herriot,

Change (with 95% CI) in outcomes by duration of type 2 diabetes

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Prevalence of statin and beta-blocker use by clinical presentation

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

A schematic representation of the possible pairwise comparisons of adherence and persistence between different medication classes. A schematic representation.

NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:

Reasons patients were excluded from the switch from atorvastatin to simvastatin J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23.

Intensity of statin treatment and possible lipid lowering treatment intolerance and/or ineffectiveness issues among patients with type 2 diabetes (aged.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Baseline characteristics of older women (NHS I), younger women (NHS II), and men (HPFS) with a history of hypertension according to thiazide use Eric N.

Hypothesized causal relations between exposures (education, immigration and income) and outcome (HbA1c at diagnosis). Hypothesized causal relations between.

Diabetes and Pregnancy

Adiponectin hypothesis for insulin resistance, the metabolic syndrome, and atherosclerosis Takashi Kadowaki, et al. J. Clin. Invest :

When queried about the supply of endocrinologists to manage diabetes, respondents felt that there are not enough endocrinologists. When queried about the.

Consequences of diabetes-related stigma.

Temporal patterns of insulin sensitivity (A), C-peptide index (B), C-peptide oDI (C), and HMWA (D) in the three racial/ethnic groups with the three treatments.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Change in markers of glycometabolism and cardiovascular risk profile.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.

Comparative monthly and annual cost savings with RHI administered with V-Go. Comparative monthly and annual cost savings with RHI administered with V-Go.

Algorithm for the metabolic management of type 2 diabetes; Reinforce lifestyle interventions at every visit and check A1C every 3 months until A1C is

Correlation of myotube AdipoR1 (A) and AdipoR2 (B) mRNA expression with insulin secretion (n = 40). Correlation of myotube AdipoR1 (A) and AdipoR2 (B)

Flow chart of patients who met inclusion/exclusion criteria in the identified study population.1 Excluded because they were living in nursing facility.

Comparison of women carrying a male fetus and those carrying a female fetus, with respect to mean adjusted blood glucose levels during the OGTT (A), mean.

MRRs and EMRRs for women with ACS

A: QTL analysis of genotyping data on chromosome 12 revealed a locus linked to glucose levels in F2 mice at 6 months of age at marker D12Mit231 with a.

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Stratified analysis of the association between GDM and abdominal circumference (AC) >90th percentile at 28 wkGA. Stratified analysis of the association.

Total plasma BCAA (A) and C3 and C5 acylcarnitine (AC) (B) concentrations in the basal state and during insulin infusion in obese subjects before and after.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Low/moderate intensity statins High intensity statins

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Arterial and hepatic sinusoidal plasma insulin levels in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

Trajectories over the 9 years of follow-up of HbA1c in all participants (n = 4,080 at baseline), stratified by the presence of a family history of diabetes,

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Comorbid conditions and concomitant medications.

Adjusted ORs for pregravid, antepartum, and postpartum factors as predictors of likelihood that a woman will gain weight between 3 and 12 months postpartum.

Mean adjusted levels in each group for the following cardiometabolic risk factors at 3 and 12 months postpartum: (A) systolic blood pressure, (B) diastolic.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Number of events, the crude incidence rate, and the crude and adjusted HR with 95% CI for the association between pioglitazone use and all-cause mortality.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

A1C at baseline and each maintenance month by treatment in the GEMINI trial, including the modified intention-to-treat population. A1C at baseline and.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence.

One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes status at baseline. One-year cumulative.

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

Initiation and adjustment of insulin regimens.

Effects of PCSK7 rs genotype and CHO diets on changes and reversion in fasting insulin levels and HOMA-IR during the 2-year intervention in white.

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

Low/moderate intensity statins High intensity statins

Risk of mortality in patients with diabetes and ESRD

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

Adjusted ORs of increasing severity of heartburn at follow-up in reference to baseline from model adjusted for BMI category, CVD history, BDI score >11,

Algorithm for the metabolic management of type 2 diabetes; Reinforce lifestyle interventions at every visit and check A1C every 3 months until A1C is

Table 6. Range Comparisons amongst Subgroups and grade levels

Cumulative distributions of A1C and fasting plasma glucose values for the U.S. population aged ≥12 years without diabetes for each survey cycle: 1999–2000,

Presentation transcript:

ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications, including ACE or ARB, statin, nonstatin cholesterol medication, other diabetes medications, and insulin. ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications, including ACE or ARB, statin, nonstatin cholesterol medication, other diabetes medications, and insulin. Gregory J. Salber et al. Clin Diabetes 2017;35:154-161 ©2017 by American Diabetes Association